Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenetic Biosciences Inc XBIO

Healthcare Biotechnology
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the... see more

Recent & Breaking News (NDAQ:XBIO)

Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update

Business Wire April 3, 2017

Xenetic Biosciences, Inc. (Nasdaq: XBIO) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire March 29, 2017

Xenetic Biosciences to Ring Nasdaq Stock Market Opening Bell on March 30, 2017

Business Wire March 29, 2017

Xenetic Biosciences Provides Update on Patent Portfolio Development

Business Wire March 27, 2017

Xenetic Biosciences to Present at the 29th Annual ROTH Conference

Business Wire March 9, 2017

Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia

Business Wire January 6, 2017

Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer

Business Wire January 4, 2017

Xenetic Biosciences to Present at Biotech Showcase 2017

Business Wire January 3, 2017

10 Biggest Mid-Day Gainers For Friday

Benzinga.com  December 30, 2016

Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer

Business Wire December 5, 2016

Xenetic Biosciences to Present at the LD Micro 2016 Annual Conference

Business Wire December 1, 2016

Xenetic Biosciences to Host Quarterly Update Conference Call and Webcast

Business Wire November 23, 2016

Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors

Business Wire November 22, 2016

Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update

Business Wire November 15, 2016

Xenetic Biosciences Announces the Closing of its $10M Public Offering

Business Wire November 7, 2016

Xenetic Biosciences Announces Nasdaq Listing of its Common Stock and Pricing of $10M Public Offering

Business Wire November 1, 2016

Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen® for Anemia

Business Wire October 10, 2016

Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

Business Wire September 22, 2016

Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer

Business Wire August 19, 2016

Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine

Business Wire August 18, 2016